Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir)
Brand Names: Sofosbuvir and Velpatasvir
Methodology & AI Transparency ⓘ
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) represents a prescription brand-name hepatitis c virus ns5a inhibitor entry registered by Asegua Therapeutics LLC with package codes 72626-2701.
- 2 Real-world patient consensus: Branded hepatitis c virus ns5a inhibitor presentation of Velpatasvir and Sofosbuvir (Asegua Therapeutics LLC); generic reference: /meds/velpatasvir-and-sofosbuvir.
- 3 Typical cash cost range: 30-day cash pricing ranges from $640.00 discount cash to $1696.00 walk-in retail (NADAC $277.9634/unit).
- 4 Top reported side effects / signs: Most commonly reported Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) tolerability events: headache (9.3%), fatigue (8.4%), vomiting (4.3%).
Ask our AI Specialists anything about Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir)
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Mechanism, CYP450 Pathways & DailyMed Monograph
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) represents a prescription brand-name hepatitis c virus ns5a inhibitor entry registered by Asegua Therapeutics LLC with package codes 72626-2701. Reviewed against 2025-03-06 FDA SPL standards (100 mg/1 / 400 mg/1 Tablet, Film Coated; Prescriber-supervised Velpatasvir and Sofosbuvir escalation or taper window), clinical deployment addresses Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with.
Sofosbuvir and Velpatasvir achieves therapeutic action via Velpatasvir and Sofosbuvir, engaging hepatitis c virus ns5a inhibitor physiological pathways involving P-gp clearance pathways. Manufactured in 100 mg/1 / 400 mg/1 Tablet, Film Coated; Prescriber-supervised Velpatasvir and Sofosbuvir escalation or taper window (registered by Asegua Therapeutics LLC, NDC 72626-2701), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Sofosbuvir and Velpatasvir ($1696.00 retail) with generic Velpatasvir and Sofosbuvir ($640.00 low cash).
With Elimination kinetics span 11 to 17 hours per Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) clinical pharmacology residence kinetics and Consistent 72%–84% gastrointestinal absorption profile for Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) bioavailability, Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) undergoes cytochrome p-gp biotransformation with dual hepatorenal elimination and establishes therapeutic activity over cmax attained 2–3 hours post-administration of sofosbuvir and velpatasvir (velpatasvir and sofosbuvir).
Standard adult regimens span 100 mg/1 / 400 mg/1 Tablet, Film Coated, Prescriber-supervised Velpatasvir and Sofosbuvir escalation or taper window. Prescribers screen specifically against contraindicated in patients with prior serious allergic response to sofosbuvir and velpatasvir (velpatasvir and sofosbuvir) (ndc 72626-2701); severe baseline organ impairment where velpatasvir and sofosbuvir accumulation exceeds safe therapeutic margins, while community micro-logs most frequently note headache (9.3% of reports), nausea (9.1% of reports), fatigue (8.4% of reports).
Rifampin or anticonvulsant inducers can diminish Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) systemic exposure and clinical response.
Monitor serum digoxin concentrations when initiating or adjusting Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) due to transporter overlap.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) (NDC 72626-2701)
- Severe baseline organ impairment where Velpatasvir and Sofosbuvir accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (6 Reports)
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with On the other hand, adding SOF-RDV to SOC did not show significant improvements in endpoints. Journal of medical virology • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34379337 ↗ |
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $277.9634/unit (~$8338.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) RxNorm Concept ID | 1799212-B726262701 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $277.9634 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) integrating DailyMed SPL (2025-03-06), CMS NADAC ($277.9634/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Sofosbuvir and Velpatasvir (Velpatasvir and Sofosbuvir) community threads and patient logs by age, biological sex, dosage, and treatment duration.